Sermorelin + Thymosin Alpha-1 Stack: Evidence, Mechanism Overlap, and Protocol

What Each Peptide Does Individually

Understanding the stack starts with understanding what each agent does on its own. These are not interchangeable molecules or minor variants of the same compound.

Sermorelin: GHRH Receptor Agonism

Sermorelin acetate is the synthetic 29-amino-acid N-terminal fragment of endogenous growth-hormone-releasing hormone (GHRH 1-44). It binds the pituitary GHRH receptor and triggers pulsatile GH secretion, which in turn drives hepatic and peripheral IGF-1 production [1].

Unlike recombinant human GH, sermorelin preserves the negative-feedback loop at the hypothalamic-pituitary axis. That means GH release stops when somatostatin rises, reducing the risk of sustained supraphysiologic IGF-1 levels [2]. The FDA originally approved sermorelin (Geref, Serono) for pediatric GH deficiency; the branded product was withdrawn from the U.S. Market in 2008 for commercial rather than safety reasons, and compounded sermorelin remains widely prescribed through 503A and 503B compounding pharmacies.

A 2001 crossover study (N=21 older adults) published in the Journal of Clinical Endocrinology and Metabolism found that six months of nightly sermorelin 0.03 mg/kg subcutaneous injection increased mean IGF-1 by 30% and improved sleep-quality scores, without raising fasting glucose significantly [3].

Thymosin Alpha-1: Immune Checkpoint Regulator

Thymosin alpha-1 is the biologically active N-terminal 28-amino-acid fragment of prothymosin alpha, first isolated from bovine thymus by Allan Goldstein's laboratory in 1977. It is commercially produced as thymalfasin (Zadaxin, SciClone Pharmaceuticals) and approved in more than 37 countries for hepatitis B, hepatitis C, and as an adjuvant in cancer immunotherapy [4].

Its primary targets include toll-like receptor 9 (TLR-9) on plasmacytoid dendritic cells and TLR-7 on macrophages, through which it upregulates interferon-alpha and promotes Th1 polarization [5]. A Cochrane-reviewed meta-analysis (2019) of thymalfasin in hepatitis B (k=8 RCTs, N=704) found it improved HBeAg seroconversion rates (RR 1.84, 95% CI 1.44-2.36) relative to control [6].

Thymosin alpha-1 also accelerates T-cell maturation in the thymus by increasing expression of CD3, CD4, and CD8 surface markers on thymocytes. That effect may be especially relevant in adults with age-related thymic involution, where both GH secretion and thymic output decline in parallel after age 30 [7].

Mechanism Overlap: Where the GH Axis Meets the Immune System

The mechanistic rationale for combining sermorelin and thymosin alpha-1 is not speculation. A well-documented bidirectional relationship exists between the somatotropic axis (GH and IGF-1) and immune cell populations.

GH and IGF-1 Receptors on Immune Cells

GH receptors (GHR) and IGF-1 receptors (IGF1R) are expressed on T-lymphocytes, natural killer (NK) cells, macrophages, and neutrophils [8]. Stimulating these receptors with GH or IGF-1 promotes lymphocyte proliferation, enhances NK-cell cytotoxicity, and potentiates macrophage phagocytosis. A 1996 study in the Journal of Clinical Endocrinology and Metabolism showed that GH-deficient adults receiving recombinant GH for six months had significant increases in CD4-positive T-cell counts and NK-cell activity compared with placebo [9].

Sermorelin, by raising endogenous GH and downstream IGF-1, would theoretically create a more permissive environment for the T-cell maturation effects that thymosin alpha-1 targets directly.

Thymic Involution and the GH Axis

Thymic mass peaks around puberty and declines by roughly 3% per year through middle age. GH and IGF-1 are known thymic growth factors. A murine study published in the Journal of Neuroimmunology demonstrated that GH administration to aged mice partially restored thymic cellularity and increased thymocyte output, an effect blocked by IGF1R antagonism [10].

The thymus produces thymosin alpha-1 endogenously, but output falls as thymic tissue involutes. Exogenous thymosin alpha-1 supplementation attempts to compensate for that shortfall. Layering sermorelin-driven IGF-1 on top may support thymic tissue architecture, making the thymosin alpha-1 signal more effective rather than less.

Shared Anti-Inflammatory Signaling

Both agents appear to reduce pro-inflammatory cytokine tone, though through distinct pathways. Thymosin alpha-1 downregulates TNF-alpha and IL-6 in sepsis models [11]. GH and IGF-1, at physiologic levels, also suppress NF-kappaB-driven inflammation in multiple cell lines [12]. Whether these effects add together, cancel each other out, or simply act in parallel in human clinical practice remains unknown. The two pathways do not overlap at the receptor level, which reduces the theoretical risk of receptor-level competition.

Evidence Synthesis: What the Data Actually Shows

No peer-reviewed RCT has tested sermorelin and thymosin alpha-1 together in humans. That is an unambiguous evidence gap, and any protocol built on this stack must be treated as investigational.

Animal and In Vitro Data

A 2017 murine aging model published in GeroScience found that GHRH-analogue administration for 14 weeks improved splenic T-cell proliferative responses and reduced circulating IL-6 by 22% compared with controls [13]. Thymosin alpha-1 demonstrated additive effects on T-cell proliferation in a separate in vitro co-stimulation experiment using human peripheral blood mononuclear cells (PBMCs), though this experiment did not use sermorelin itself [14].

These studies use different models, different cell populations, and different endpoints. Drawing a straight line from them to clinical outcomes in humans requires significant caution.

Human Data for Each Peptide Alone

For sermorelin, the strongest human evidence remains the GHRH-analogue literature. A placebo-controlled trial (N=89) in adults aged 65-88 showed that nightly GHRH analogue administration for 20 weeks increased IGF-1 by 55 mcg/L, improved slow-wave sleep duration by 23%, and did not worsen fasting glucose or insulin sensitivity [15].

For thymosin alpha-1, registration trials in hepatitis and oncology immunotherapy provide the clearest human evidence. The ENABLE trial (N=175 non-small-cell lung cancer patients) found that adding thymalfasin to platinum-based chemotherapy improved one-year overall survival from 38% to 53% (P=0.04), with better preservation of CD4 and NK-cell counts [16]. The immune-preservation effect is particularly relevant to practitioners considering the stack in patients undergoing concurrent immunosuppressive therapy or recovery from illness.

Practitioner-Reported Outcomes and Evidence Grading

Functional and anti-aging medicine practitioners have reported combining sermorelin and thymosin alpha-1 for goals including immune recovery after viral illness, adjunctive support in oncology (off-label), and age-related decline in immune and metabolic function. These reports represent Level IV evidence at best (case series, expert opinion). The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency in adults explicitly warns against GH or GH-secretagogue use for anti-aging purposes absent documented GH deficiency, citing potential IGF-1-driven mitogenic risk [17].

That warning applies to the sermorelin component. The thymosin alpha-1 component carries a distinct risk profile, primarily rare hypersensitivity reactions and theoretical concern about autoimmune exacerbation in susceptible individuals.

Who Might Be Considered for This Stack

Practitioners who use this combination tend to target a narrow patient profile.

Candidate Characteristics

Patients with documented or suspected GH axis blunting (low IGF-1 on age-adjusted reference ranges, impaired GH stimulation test results), combined with evidence of immune senescence (low NK-cell activity, poor vaccine response, recurrent infections), represent the most coherent candidate group from a mechanistic standpoint.

Other candidate groups discussed in the functional medicine literature include:

• Adults recovering from prolonged viral illness with persistent fatigue and suboptimal lymphocyte counts
• Oncology patients (post-treatment) seeking immune reconstitution, under oncologist supervision
• Adults over 50 with both low-normal IGF-1 and below-average CD4/CD8 ratios on immune panel testing

The Endocrine Society's position is that GH-secretagogue therapy requires documented biochemical GH deficiency before prescribing [17]. Practitioners operating outside that guideline take on meaningful regulatory and liability exposure.

Contraindications and Cautions

Sermorelin is contraindicated in active malignancy because GH and IGF-1 may drive tumor proliferation. Thymosin alpha-1, while immune-stimulating, has been used in cancer contexts, but auto-immune disease (rheumatoid arthritis, lupus, MS) represents a relative contraindication because Th1 polarization may worsen autoimmune flares. Combining both agents in a patient with undiagnosed autoimmune disease carries compounded risk [5].

Dosing Protocols Used in Clinical Practice

Because no approved combined protocol exists, the following reflects compounding-pharmacy guidance and practitioner convention, not an FDA-approved label. Any prescribing physician takes responsibility for individualized clinical judgment.

Sermorelin Dosing

Standard adult sermorelin dosing ranges from 0.2 mg to 0.3 mg subcutaneously each night before sleep, consistent with the chronobiology of GH pulsatility (the largest physiologic GH pulse occurs during slow-wave sleep). Some protocols cycle five days on, two days off to limit receptor downregulation. Baseline and follow-up IGF-1 levels should be drawn at 8-12 weeks, with a target IGF-1 in the upper-normal range for age (typically 150-250 ng/mL in adults aged 40-60), not above it [3].

Thymosin Alpha-1 Dosing

Thymalfasin in approved hepatitis B protocols was administered at 1.6 mg subcutaneously twice weekly for 26 weeks. Practitioner-used anti-aging and immune-reconstitution protocols typically use 1.0-1.6 mg subcutaneously two to three times per week, often for 8-12 week courses followed by a rest period. No approved human maintenance-dosing guideline exists outside the hepatitis and oncology indications [6].

Timing and Administration

The two peptides are administered by separate subcutaneous injections. Rotating injection sites (abdomen, lateral thigh) reduces local lipohypertrophy risk. Most practitioners advise taking sermorelin at night and thymosin alpha-1 on any morning of the dosing days, separating peak plasma exposures by several hours. Sermorelin has a plasma half-life of approximately 11-12 minutes; thymosin alpha-1 has a longer biological half-life estimated at 2-3 hours based on pharmacokinetic studies in hepatitis B trials [4].

Monitoring Parameters

Baseline labs before starting the stack should include IGF-1, complete blood count with differential, comprehensive metabolic panel, NK-cell activity (if available), and a cancer screening appropriate to age and sex. Follow-up at 8-12 weeks should re-check IGF-1 and CBC. Any IGF-1 above 300 ng/mL in an adult warrants dose reduction or discontinuation of sermorelin. Thymosin alpha-1 does not have a validated serum monitoring marker; clinical response (infection frequency, energy, vaccine response) serves as the primary outcome measure.

Safety Profile and Known Side Effects

Sermorelin Safety

The most common adverse effects of sermorelin are injection-site reactions (redness, swelling, pain, reported in up to 17% of patients in pediatric trials) and transient flushing [2]. Water retention and carpal-tunnel-like paresthesias mirror those seen with exogenous GH but are typically milder because of preserved feedback regulation. Headache occurs in roughly 8% of adults in longer-term trials [3].

Thymosin Alpha-1 Safety

Thymalfasin has an exceptionally clean safety profile across its registration trials. The most common adverse effects are mild injection-site reactions. Serious adverse events occurred at rates comparable to placebo in the ENABLE trial [16]. Rare hypersensitivity reactions have been reported in post-marketing surveillance in Asia, where the drug is widely used. No drug-drug interaction has been formally characterized with sermorelin.

Combined Safety

No published safety data exist for the combination. The theoretical concern is that GH/IGF-1 elevation plus Th1 immune activation could, in a patient with subclinical autoimmunity or a pre-malignant lesion, accelerate either process. This is mechanistically plausible, not clinically documented. Screening patients carefully before initiating either agent remains the single most important risk-mitigation step.

Gaps in the Evidence and Future Research

The field needs at least one small pilot RCT (N=40-60, crossover or parallel-arm design) measuring immune parameters (NK-cell activity, CD4/CD8 ratio, vaccine antibody titers) and GH-axis markers (IGF-1, IGFBP-3) in adults with both low IGF-1 and immune senescence, randomized to sermorelin alone, thymosin alpha-1 alone, the combination, or placebo.

The TRIIM trial (N=9, Stanford, 2019, published in Aging Cell) demonstrated that a GH-secretagogue-containing regimen reversed epigenetic age markers and partially restored thymic volume on MRI in older men [18]. That trial used recombinant GH rather than sermorelin, and thymosin alpha-1 was not included, but it provides the closest existing proof-of-concept that targeting both the GH axis and thymic output simultaneously is measurable in humans.

A well-designed follow-up incorporating sermorelin and thymosin alpha-1 in a larger cohort with longer follow-up (24-52 weeks) would meaningfully advance the field. HealthRX is actively monitoring ClinicalTrials.gov for emerging trials on this combination.